Philippe Archinard

bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium

bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium

bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium

Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD.

bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium

bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.

bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.

Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD.

Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD.

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France.

Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD.

Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD.

Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.